Citations

Clear

750 citation(s) found for "Lowe, Val".

Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685
Lowe, Val J. , Duan, Fenghai , Subramaniam, Rathan M. , Sicks, JoRean D., Romanoff, Justin , Bartel, Twyla B. , Yu, Jian Q. , Cognetti, David M. , Stack, Brendan C. , Nussenbaum, Brian A. , Richmon, Jeremy D. , Arnold, Charles D.

Mayo Clinic

Journal of Clinical Oncology | February 15, 2019 | Volume: 37 | Issue: 20 | Pages: 1704-1712

10.1200/jco.18.01182 | PMID 30768363 Get It

PURPOSE The objective of this study was to determine the negative predictive value (NPV) of positron emission tomography (PET)/computed tomography (CT) for the clinically N0 neck on the basis of neck dissection. METHODS Participants with newly diagnosed, first-time, head and neck squamous cell carcinoma (HNSCC) and at least one clinically N0 neck side for which dissection was planned were included. A total of 287 participants were prospectively enrolled from 23 American College of Radiology Imaging Network-qualified institutions. PET/CT was compared with findings at neck dissection. RESULTS PET/CT scans and pathology findings were available for 270 N0 neck sides from 212 participants. For visual assessment, the NPV specific to the clinical-N0 sides was 0.868 (95% CI, 0.803 to 0.925). For dichotomized maximum standardized uptake value, the NPVs specific to the nodal basins were 0.940 (95% CI, 0.928 to 0.952) and 0.937 (95% CI, 0.925 to 0.949) at prespecified cutoffs of 2.5 and 3.5, respectively. The optimal cutoff maximum standardized uptake value was determined to be 1.8, with an NPV of 0.942 (95% CI, 0.930 to 0.953). The PET/CT-informed surgical treatment plan was changed in 51 of 237 participants (22%) compared with the PET/CT-blinded surgical plan. In 34 participants (14%), this led to planned dissection of additional nodal levels. In 12 participants (5%), this led to fewer planned dissected nodal levels. Negative PET/CT scans in N0 necks was true negative in 87% and false negative in 13%. CONCLUSION [18F]fluorodeoxyglucose-PET/CT has high NPV for the N0 neck in T2 to T4 HNSCC. The surgical treatment plans on the basis of PET/CT findings may be changed in approximately 22% of this group. These findings suggest that [18F]fluorodeoxyglucose-PET/CT may assist the clinician in deciding on the best therapy for the clinically N0 neck in HNSCC. Well-designed clinical trials should be performed to test the outcome of omitting neck dissection by using PET/CT.
Abstract 104: Topographic White Matter Hyperintensity Patterns Associated With Alzheimer Pathologies
Graff‐Radford, Jonathan , Arenaza-Urquijo, Eider de, Brown, Robert D. , Ward, Chadwick P., Przybelski, Scott A. , Lenick, Timothy G, Gunter, Jeffrey L. , Petersen, Ronald C. , Lowe, Val J. , Arenaza‐Urquijo, Eider M. , Arenaza-Urquijo, Eider M , Schwarz, Christopher G. , Mielke, Michelle M. , Rabinstein, Alejandro A. , Kantarci, Kejal , Knopman, David S. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.104 Get It

Background: Although white matter hyperintensities (WMH) have been viewed as a marker of vascular disease, pathology studies have found an association of WMH with Alzheimer’s disease (AD) pathologies. Our objective was to investigate the topographic patterns of WMH associated with AD biomarkers. Methods: From the population-based Mayo Clinic Study of aging, 434 non-demented participants with FLAIR-MRI, tau-PET and PiB-PET scans were identified. A subset had microbleeds on T2* GRE scans. We ran SPM12 based voxel-wise multiple regression analyses to detect WMH regions associated with AD biomarkers (global amyloid from PiB-PET and meta-ROI tau uptake from tau-PET) adjusting for age, sex, and hypertension. For amyloid associations, we additionally adjusted for tau and vice versa. Results: Topographic patterns of WMH associated with amyloid after both voxel and cluster level corrections primarily included periventricular WMH (frontal and parietal lobes). Masks with lenient threshold (greater detection sensitivity) and strict thresholds (greater detection specificity) are shown in the figure. (A) and (B) show the areas of positive associations between PIB ratio and WMHs adjusted by age, sex, education, hypertension and Tau meta ROI. The sensitive mask (A) was thresholded at FDR p<0.05 at voxel level and FWE p<0.05 at cluster level. The specific mask (B) was thresholded at FDR p<0.001 at voxel level and FDR p<0.05 at cluster level. (C) Shows the frequency of WMHs in the study sample, ranging from infrequent (dark blue) to frequent (green to red). Both the sensitive (p<0.001, Cohen’s D=0.615) and specific WMH maps (p<0.001, Cohen’s D = 0.705) were associated with microbleeds. No WMH regions were associated with tau. Conclusion: Amyloid but not tau load on PET was associated with WMH topographically. The WMH regions associated with amyloid were associated with CMBs suggesting that cerebral amyloid angiopathy may be contributing to the relationship between amyloid and WMH.
Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects
Lundt, Emily S. , Therneau, Terry M. , Vemuri, Prashanthi , Lowe, Val J. , Kantarci, Kejal , Gunter, Jeffrey L. , Senjem, Matthew L. , Graff-Radford, Jon, Albertson, Sabrina M., Petersen, Ronald C. , Jack, Clifford R. , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Boeve, Bradley F. , Jones, David T. , Graff-Radford, Jon, Schwarz, Christopher G. , Lundt, Emily S

Mayo Clinic

Brain | January 20, 2019 | Volume: 142 | Issue: 4 | Pages: 1148-1160

10.1093/brain/awz025 | PMID 30759182 Get It

AbstractAs more biomarkers for Alzheimer’s disease and age-related brain conditions become available, more sophisticated analytic approaches are needed to take full advantage of the information they convey. Most work has been done using categorical approaches but the joint relationships of tau PET, amyloid PET and cortical thickness in their continuous distributions to cognition have been under-explored. We evaluated non-demented subjects over age 50 years in the Mayo Clinic Study of Aging, 2037 of whom had undergone 3 T MRI scan, 985 amyloid PET scan with 11C-Pittsburgh compound B (PIB) and MRI, and 577 PIB-PET, 18F-AV1451 flortaucipir PET and MRI. Participants received a nine-test cognitive battery. Three test scores (logical memory delayed recall, visual reproduction delayed recall and auditory verbal learning test delayed recall) were used to generate a memory composite z-score. We used Gradient Boosting Machine models to analyse the relationship between regional cortical thickness, flortaucipir PET signal, PIB-PET signal and memory z-scores. Age, education, sex and number of test exposures were included in the model as covariates. In this population-based study of non-demented subjects, most of the associations between biomarkers and memory z-scores accrued after 70 years of age. Entorhinal cortex exhibited the strongest associations between biomarkers and memory z-scores. Other temporal regions showed similar but attenuated associations, and non-temporal regions had negligible associations between memory z-scores and biomarkers. Entorhinal flortaucipir PET signal, PIB-PET signal and entorhinal cortical thickness were independently and additively associated with declining memory z-scores. In contrast to global PIB-PET signal where only very high amyloid-β levels were associated low memory z-scores, entorhinal flortaucipir PET signal just above background levels was associated with low memory z-scores. The lowest memory z-scores occurred with the confluence of elevated entorhinal flortaucipir PET signal and lower entorhinal cortical thickness.
18F‐AV‐1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy
Nedelská, Zuzana , Josephs, Keith A. , Graff‐Radford, Jonathan, Przybelski, Scott A. , Lesnick, Timothy G. , Drubach, Daniel A., Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Whitwell, Jennifer , Kantarci, Kejal , Jack, Clifford R , Nedelska, Zuzana , Kantarci, Kejal , Graff‐Radford, Jonathan , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Movement Disorders | January 8, 2019 | Volume: 34 | Issue: 3 | Pages: 344-352

10.1002/mds.27603 | PMID 30615804 Get It

AbstractBackgroundPosterior cortical atrophy and dementia with Lewy bodies are 2 distinct clinical syndromes, yet they can overlap in symptoms and occipital hypometabolism. Patients with dementia with Lewy bodies often have overlapping Alzheimer's disease pathology. Similarly, Lewy bodies can be found in patients with posterior cortical atrophy. We investigated differences in the distribution and magnitude of F18‐AV‐1451 uptake in patients with these 2 syndromes.MethodsConsecutive patients with probable dementia with Lewy bodies (n = 33), posterior cortical atrophy (n = 18), and cognitively unimpaired controls (n = 100) underwent 18F‐AV‐1451 positron emission tomography. Regional differences in AV‐1451 uptake were assessed using voxel‐wise and an atlas‐based approach. The greatest differences in AV‐1451 uptake between patient groups were identified using area under receiver operating curve statistics, and a composite region was derived.ResultsAV‐1451 uptake in both patient groups was predominantly localized to the lateral occipital regions, but the magnitude of uptake was markedly greater in posterior cortical atrophy compared with dementia with Lewy bodies. The posterior cortical atrophy group showed the greatest AV‐1451 uptake throughout all the gray matter compared with that in other groups. The occipital composite region, consisting of superior, middle, and inferior occipital cortices, distinguished posterior cortical atrophy from dementia with Lewy bodies (area under the curve >0.97; P < 0.001, Bonferroni‐corrected) with excellent sensitivity (88%) and specificity (100%).ConclusionsPosterior cortical atrophy and dementia with Lewy bodies can share clinical features, and although the pattern of AV‐1451 uptake in occipital cortices overlaps between these 2 syndromes, its magnitude is significantly higher in posterior cortical atrophy. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease
Sintini, Irene , Schwarz, Christopher G. , Martin, Peter R. , Graff‐Radford, Jonathan, Senjem, Matthew L. , Spychalla, Anthony J., Drubach, Daniel A., Lowe, Val J. , Jack, Clifford R. , Josephs, Keith A. , Whitwell, Jennifer L. , Jack, Clifford R , Schwarz, Christopher G , Senjem, Matthew L , Graff‐Radford, Jonathan , Machulda, Mary M. , Reid, Robert I.

Mayo Clinic

Human Brain Mapping | December 14, 2018 | Volume: 40 | Issue: 5 | Pages: 1618-1631

10.1002/hbm.24473 | PMID 30549156 Get It

AbstractAlzheimer's disease (AD) can present with atypical clinical forms where the prominent domain of deficit is not memory, that is, atypical AD. Atypical AD patients show cortical atrophy on MRI, hypometabolism on [18F]fluorodeoxyglucose (FDG) PET, tau uptake on [18F]AV‐1451 PET, and white matter tract degeneration on diffusion tensor imaging (DTI). How these disease processes relate to each other locally and distantly remains unclear. We aimed to examine multimodal neuroimaging relationships in individuals with atypical AD, using univariate and multivariate techniques at region‐ and voxel‐level. Forty atypical AD patients underwent MRI, FDG‐PET, tau‐PET, beta‐amyloid PET, and DTI. Patients were all beta‐amyloid positive. Partial Pearson's correlations were performed between tau and FDG standardized uptake value ratios, gray matter MRI‐volumes and white matter tract fractional anisotropy. Sparse canonical correlation analysis was applied to identify multivariate relationships between the same quantities. Voxel‐level associations across modalities were also assessed. Tau showed strong local negative correlations with FDG metabolism in the occipital and frontal lobes. Tau in frontal and parietal regions was negatively associated with temporoparietal gray matter MRI‐volume. Fractional anisotropy in a set of posterior white matter tracts, including the splenium of the corpus callosum, cingulum, and posterior thalamic radiation, was negatively correlated with parietal and occipital tau, atrophy and, predominantly, with hypometabolism. These results support the view that tau is the driving force behind neurodegeneration in atypical AD, and that a breakdown in structural connectivity is related to cortical neurodegeneration, particularly hypometabolism.
Predicting Progression to Mild Cognitive Impairment
Petersen, Ronald C. , Lundt, Emily S. , Therneau, Terry M. , Weigand, Stephen D. , Roberts, Rosebud O., Lowe, Val J. , Kremers, Walter K. , Geda, Yonas E. , Jack, Clifford R. , Jack, Clifford R , Geda, Yonas E , Kremers, Walter K , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Lundt, Emily S

Mayo Clinic

Annals of Neurology | December 6, 2018 | Volume: 85 | Issue: 1 | Pages: 155-160

10.1002/ana.25388 | PMID 30521086 Get It

Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population‐based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75‐year‐old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.
Amyloid- and tau-PET imaging in a familial prion kindred
Townley, Ryan , Graff‐Radford, Jonathan , Botha, Hugo , Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Townley, Ryan A, Jack, Clifford R , Botha, Hugo , Jones, David T. , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Neurology Genetics | December 4, 2018 | Volume: 4 | Issue: 6 | Pages: No page available

10.1212/nxg.0000000000000290 | PMID 30584595 Get It

MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy
Whitwell, Jennifer L. , Tosakulwong, Nirubol , Botha, Hugo , Senjem, Matthew L. , Spychalla, Anthony J., Ahlskog, J. Eric , Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Schwarz, Christopher G. , Knopman, David S.

Mayo Clinic

Movement Disorders | November 23, 2018 | Volume: 34 | Issue: 1 | Pages: 105-113

10.1002/mds.27546 | PMID 30468693 Get It

AbstractBackgroundElevated uptake of the [18F]AV‐1451 tau‐PET ligand has been observed cross‐sectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [18F]AV‐1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy.MethodsSixteen subjects with PSP underwent 2 serial [18F]AV‐1451 tau‐PET scans and 3‐Tesla MRI over 12 months and were age‐ and sex‐matched to 39 healthy controls with longitudinal [18F]AV‐1451 PET. Median [18F]AV‐1451 uptake was calculated for each scan for regions of interest across the brain and divided by uptake in cerebellar crus to create standard uptake value ratios. Midbrain volume on MRI was also calculated for each scan. Sample sizes required to power placebo‐controlled treatment trials were calculated.ResultsRate of midbrain atrophy was significantly increased in PSP compared with controls. [18F]AV‐1451 regional change measures were significantly increased in PSP compared with controls in the pallidum, precentral cortex, dentate nucleus of the cerebellum, and midbrain. Change over time in the PSP Rating Scale correlated with change in midbrain volume but did not correlate with change in the [18F]AV‐1451 measures. Smallest sample‐size estimates were obtained with rate of midbrain atrophy, followed by the PSP Rating Scale, with both outperforming [18F]AV‐1451 measures.Conclusions[18F]AV‐1451 tau‐PET measures increase over time in subjects with PSP, but longitudinal [18F]AV‐1451 measures may not perform as well as rate of midbrain atrophy as biomarkers for PSP clinical trials. © 2018 International Parkinson and Movement Disorder Society